DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics to Present at October Investor Conferences

28 сен 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

20 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

05 сен 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

03 авг 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Healthcare Conference

01 июн 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

25 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

17 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

11 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

03 май 2023 06:35:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

02 май 2023 15:46:03 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

23 мар 2023 06:30:17 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

20 мар 2023 06:30:24 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

07 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

02 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 ноя 2022 06:30:01 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Investor Conferences in November

02 ноя 2022 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

31 окт 2022 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress

11 окт 2022 15:10:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

27 сен 2022 06:30:00 Источник Nasdaq GlobeNewswire